BioPorto A/S
OTC: THOXF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Carsten Buhl
- Employees
- 48
- Headquarters
- Hellerup, Denmark
- IPO year
- 2019
- Market cap
- $73.8M
- Website
- https://bioporto.com
Loading THOXF…
Loading profile data…Frequently asked questions about THOXF
What does BioPorto A/S (THOXF) do?
BioPorto A/S is an in-vitro diagnostics firm that supplies diagnostic tools and antibodies globally to medical professionals and scientists. Its product portfolio includes the neutrophil gelatinase-associated lipocalin (NGAL) test – a particle-enhanced turbidimetric assay designed to quantify NGAL levels, which complements existing clinical asse...
Where does THOXF trade?
BioPorto A/S (THOXF) trades on the Other OTC.
What sector is THOXF in?
BioPorto A/S (THOXF) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of BioPorto A/S?
Carsten Buhl is the chief executive officer of BioPorto A/S (THOXF).
Where is BioPorto A/S headquartered?
BioPorto A/S is headquartered in Denmark.
Does THOXF pay a dividend?
BioPorto A/S (THOXF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did THOXF go public?
BioPorto A/S (THOXF) completed its initial public offering in 2019.